2 Fletcher JA. Role of KIT and Platelet-Derived Growth Factor Receptors as Oncoproteins. Seminars in Oncology 2004; 31: 4–11. 3 Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. Journal of Pathology 2001; 193: 505–510. 4 Tefferi1 A, Gilliland DG. Oncogenes in Myeloproliferative Disorders. Cell Cycle 2007; 5: 550–566. 5 Hiwatari M, Taki T, Tsuchida M, Hanada R, Hongo T, Sako M et al. Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor alpha (PDGFRA) gene in childhood acute myeloid leukemia with t (8; 21)(q22; q22) or inv (16)(p13q22). Leukemia 2005; 19: 476–477. 6 Burgstaller S, Kreil S, Waghorn K, Metzgeroth G, Preudhomme C, Zoi K et al. The severity of FIP1L1–PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia 2007; 21: 2428–2432. 7 Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX et al. AML1–ETO and C–KIT mutation/overexpression in t (8; 21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec.